发布求助
文献互助 智能选刊 最新文献

Trends in molecular medicine最新文献

筛选
英文 中文
AAV vectors: an emerging strategy for chronic pain management. AAV载体：慢性疼痛管理的新兴策略。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-18 DOI: 10.1016/j.molmed.2025.08.008
Romina Nassini, Martina Chieca, Matilde Marini, Lorenzo Landini, Francesco De Logu
{"title":"AAV vectors: an emerging strategy for chronic pain management.","authors":"Romina Nassini, Martina Chieca, Matilde Marini, Lorenzo Landini, Francesco De Logu","doi":"10.1016/j.molmed.2025.08.008","DOIUrl":"https://doi.org/10.1016/j.molmed.2025.08.008","url":null,"abstract":"<p><p>Chronic pain affects millions of people worldwide and represents a crucial public health issue. A growing body of preclinical evidence suggests that adeno-associated virus (AAV) vectors are a powerful gene therapy tool for chronic pain management. We systematically summarize how AAV vectors, by targeting molecular pain pathways in neuronal and non-neuronal cells, may offer precise and sustained pain relief. We provide an overview of the latest findings and emerging concepts in this area, and discuss preclinical innovations in neuropathic, inflammatory and cancer-related pain. We also present clinical data on pain modulation by AAV in osteoarthritis (OA) patients. Finally, we provide a thorough analysis of key concerns about AAV therapy, including potential immune responses, toxicity, and adverse effects.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":13.8,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MAFLD: a ferroptotic disease. MAFLD：一种嗜铁性疾病。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-09 DOI: 10.1016/j.molmed.2025.08.006
Shaojie Cui, Jin Ye
{"title":"MAFLD: a ferroptotic disease.","authors":"Shaojie Cui, Jin Ye","doi":"10.1016/j.molmed.2025.08.006","DOIUrl":"10.1016/j.molmed.2025.08.006","url":null,"abstract":"<p><p>Ferroptosis, a regulated cell death pathway driven by iron-catalyzed lipid peroxidation, has recently been implicated as a major cause of hepatic injury in metabolic dysfunction-associated fatty liver disease (MAFLD). This review highlights how the identification of hyperoxidized peroxiredoxin 3 (PRDX3) as a ferroptosis-specific marker has led to the discovery that ferroptosis contributes to liver injury in MAFLD, and summarizes other emerging evidence connecting ferroptosis to MAFLD pathogenesis. These new findings suggest that dietary fat composition and genetic variants such as PNPLA3(I148M) may affect the progression of MAFLD by regulating cellular sensitivity to ferroptosis. Recognizing MAFLD as a ferroptotic disease provides novel insights into the pathogenesis of the disease, and supports the exploration of ferroptosis as a potential target for therapeutic intervention.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":13.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12431636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human cardiac organoids for disease modeling and drug discovery. 用于疾病建模和药物发现的人类心脏类器官。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-05 DOI: 10.1016/j.molmed.2025.08.004
Sean Escopete, Madelyn Arzt, Maedeh Mozneb, Jemima Moses, Arun Sharma
{"title":"Human cardiac organoids for disease modeling and drug discovery.","authors":"Sean Escopete, Madelyn Arzt, Maedeh Mozneb, Jemima Moses, Arun Sharma","doi":"10.1016/j.molmed.2025.08.004","DOIUrl":"https://doi.org/10.1016/j.molmed.2025.08.004","url":null,"abstract":"<p><p>Cardiac organoids are 3D self-assembling structures that recapitulate some of the functional, structural, and cellular aspects of the developing heart. Cardiac organoid modeling has overcome many of the limitations of current cardiac modeling systems by providing a human-relevant, multicellular, spatially advanced model that can replicate early key developmental stages of human cardiogenesis. Recent advancements in cardiac organoid modeling have enabled further understanding of cardiogenesis, cardiovascular disease, and drug-induced cardiotoxicity. Emerging tools to effectively characterize cardiac organoid models to understand their morphology, function, and cellular phenotype will enable further understanding of cardiac development, cardiovascular disease, and preclinical drug discovery.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":13.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting pathological ERK1/2 signaling in cancer and beyond. 靶向肿瘤及其他肿瘤的病理ERK1/2信号。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-05 DOI: 10.1016/j.molmed.2025.08.001
Constanze Schanbacher, Maria-Elisabeth Goebeler, Brenda Gerull, Kristina Lorenz
{"title":"Targeting pathological ERK1/2 signaling in cancer and beyond.","authors":"Constanze Schanbacher, Maria-Elisabeth Goebeler, Brenda Gerull, Kristina Lorenz","doi":"10.1016/j.molmed.2025.08.001","DOIUrl":"https://doi.org/10.1016/j.molmed.2025.08.001","url":null,"abstract":"<p><p>Dysregulation of the RAF-MEK-ERK1/2 pathway is involved in the pathoetiology of many diseases. Its central role in cancer has led to the development of drugs targeting upstream receptors, RAS, and kinases in the extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) signaling cascade. The use of these drugs in cancer therapy - together with ongoing monitoring of their effectiveness, evolving side-effects, and resistance mechanisms - has expanded our knowledge of both the physiological and pathological functions of ERK1/2 and could thus provide potential alternative therapeutic strategies. In this review we discuss the latest insights into targeting of MEK1/2 and ERK1/2 and the transfer of the lessons learned from cancer treatment to further indications involving ERK1/2 dysregulation such as genetic disorders (RASopathies) and beyond.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":13.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical gene therapy restores hearing: a paradigm shift. 临床基因治疗恢复听力：范式转变。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-03 DOI: 10.1016/j.molmed.2025.07.007
Shuang Han, Ziting Chen, Daqi Wang, Luoying Jiang, Xintai Fan, Jiake Zhong, Chong Cui, Yuxin Chen, Jun Lv, Jiajia Zhang, Yu Zhao, Dazhi Shi, Wei Lu, Suijun Chen, Hongqun Jiang, Wei Yuan, Qin Wang, GuoDong Feng, Xuezhong Liu, Huijun Yuan, Fan-Gang Zeng, Huawei Li, Zheng-Yi Chen, Yilai Shu
{"title":"Clinical gene therapy restores hearing: a paradigm shift.","authors":"Shuang Han, Ziting Chen, Daqi Wang, Luoying Jiang, Xintai Fan, Jiake Zhong, Chong Cui, Yuxin Chen, Jun Lv, Jiajia Zhang, Yu Zhao, Dazhi Shi, Wei Lu, Suijun Chen, Hongqun Jiang, Wei Yuan, Qin Wang, GuoDong Feng, Xuezhong Liu, Huijun Yuan, Fan-Gang Zeng, Huawei Li, Zheng-Yi Chen, Yilai Shu","doi":"10.1016/j.molmed.2025.07.007","DOIUrl":"https://doi.org/10.1016/j.molmed.2025.07.007","url":null,"abstract":"<p><p>Recent breakthroughs in gene therapy for autosomal recessive deafness 9 (DFNB9) caused by OTOF mutations have transformed treatment paradigms for hereditary hearing loss (HHL). To date, eight clinical trials targeting DFNB9 have been registered in 51 centers across eight countries, demonstrating the rapid progress of gene therapy in auditory medicine. These pioneering studies establish the framework for the clinical translation of gene therapy targeting HHL. This review synthesizes progress in OTOF-related clinical trials, highlighting translational foci such as inner ear drug delivery, trial design, safety assessments, and auditory restoration outcomes. Key challenges in optimizing future therapeutic strategies - including addressing anatomical constraints, refining patient selection criteria, and standardizing outcome measures - are critically examined.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":13.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial biology - unravelling complexity within the glioblastoma microenvironment. 空间生物学——揭示胶质母细胞瘤微环境的复杂性。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-01 Epub Date: 2025-02-10 DOI: 10.1016/j.molmed.2025.01.014
Stephen D Robinson, Chrysa Filippopoulou, Simoni Besta, Mark Samuels, Andrea Lauer Betrán, Maha Abu Ajamieh, Viviana Vella, William Jones, Georgios Giamas
{"title":"Spatial biology - unravelling complexity within the glioblastoma microenvironment.","authors":"Stephen D Robinson, Chrysa Filippopoulou, Simoni Besta, Mark Samuels, Andrea Lauer Betrán, Maha Abu Ajamieh, Viviana Vella, William Jones, Georgios Giamas","doi":"10.1016/j.molmed.2025.01.014","DOIUrl":"10.1016/j.molmed.2025.01.014","url":null,"abstract":"<p><p>The advent and refinement of state-of-the-art spatial biology technologies have facilitated analysis that combines the advantages of high-throughput single cell analysis with techniques that preserve tissue architecture. This combination of cellular phenotyping with retained spatial context provides a much greater understanding of cellular interactions within the tumour microenvironment (TME). For glioblastoma, with its significant intra-tumoural heterogeneity, cellular plasticity, and complex TME, appreciating and understanding these spatial patterns may prove key to improving patient outcomes. This review examines the advances in spatial biology techniques, discusses how these methodologies are being applied to study glioblastoma, and explores how spatial information improves understanding of the TME. Ultimately, it is this spatial context that will accelerate the identification of more effective treatments for glioblastoma.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"846-859"},"PeriodicalIF":13.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is there a place for engineered immune cell therapies in autoimmune diseases? 工程免疫细胞疗法在自身免疫性疾病中有一席之地吗？
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-01 Epub Date: 2025-02-20 DOI: 10.1016/j.molmed.2025.01.011
Luca Perico, Federica Casiraghi, Ariela Benigni, Giuseppe Remuzzi
{"title":"Is there a place for engineered immune cell therapies in autoimmune diseases?","authors":"Luca Perico, Federica Casiraghi, Ariela Benigni, Giuseppe Remuzzi","doi":"10.1016/j.molmed.2025.01.011","DOIUrl":"10.1016/j.molmed.2025.01.011","url":null,"abstract":"<p><p>The ability to engineer immune cells yielded a transformative era in oncology. Early clinical trials demonstrated the efficacy of chimeric antigen receptor (CAR) T cells in resetting the immune system, motivating the expansion of this treatment beyond cancer, including autoimmune conditions. In this review, we discuss the current state of CAR T cell research in autoimmune diseases, examining the main challenges that limit widespread adoption of this therapy, such as complex isolation protocols, stringent immunosuppression, risk of secondary malignancies, and variable efficacy. We also review the studies addressing these limitations by development of off-the-shelf allogeneic CAR T cells, tunable safety systems, and antigen-specific therapies, which hold the potential to improve safety and accessibility of this treatment in clinical practice.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"827-845"},"PeriodicalIF":13.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for capsid-targeting antiretrovirals in pre-exposure prophylaxis. 衣壳靶向抗逆转录病毒药物用于暴露前预防的考虑。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-01 Epub Date: 2025-02-27 DOI: 10.1016/j.molmed.2025.01.013
William M McFadden, Mia Faerch, Karen A Kirby, Robert A Dick, Bruce E Torbett, Stefan G Sarafianos
{"title":"Considerations for capsid-targeting antiretrovirals in pre-exposure prophylaxis.","authors":"William M McFadden, Mia Faerch, Karen A Kirby, Robert A Dick, Bruce E Torbett, Stefan G Sarafianos","doi":"10.1016/j.molmed.2025.01.013","DOIUrl":"10.1016/j.molmed.2025.01.013","url":null,"abstract":"<p><p>Antiretroviral therapy (ART) impairs viral replication in people living with HIV (PLWH) by suppressing infection or spread. However, not all treatment strategies apply to preventive applications like pre-exposure prophylaxis (PrEP) for uninfected individuals. To prevent the establishment of HIV infection, PrEP must block viral replication either before, or at the stage of integration into the host genome. A promising PrEP approach under investigation utilizes lenacapavir (LEN), which targets the HIV-1 capsid protein (CA) potently before integration. LEN, a first-in-class antiretroviral, has shown high protective efficacy in the ongoing PURPOSE trials thus far. Here, we discuss clinical investigations of LEN, theoretical suitability of preclinical CA-binding antivirals in PrEP, and other key considerations for preventing HIV-1 infection by targeting the capsid.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"801-813"},"PeriodicalIF":13.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gasdermins in pyroptosis, inflammation, and cancer. 焦亡、炎症和癌症中的气胚乳。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-01 Epub Date: 2025-04-30 DOI: 10.1016/j.molmed.2025.04.003
Rui Min, Yang Bai, Ning-Rui Wang, Xing Liu
{"title":"Gasdermins in pyroptosis, inflammation, and cancer.","authors":"Rui Min, Yang Bai, Ning-Rui Wang, Xing Liu","doi":"10.1016/j.molmed.2025.04.003","DOIUrl":"10.1016/j.molmed.2025.04.003","url":null,"abstract":"<p><p>Pyroptosis is a type of programmed inflammatory cell death characterized by balloon-like swelling, membrane rupture, and the release of inflammatory cytokines and danger signals. Pyroptosis is directly triggered by activated gasdermins (GSDMs) which bind to membrane phospholipids, oligomerize, and form pores in cell membranes. GSDM activation is mediated by various effector proteases via cleavage of the linker region or post-translational modification to release the active N-terminal fragment in response to a variety of pathogenic or intrinsic danger signals. GSDM-mediated pyroptosis is involved in the pathogenesis of an array of infectious and inflammatory diseases and cancers. This review discusses recent advances related to the physiological and pathological functions of GSDM-mediated pyroptosis, as well as therapeutic strategies targeting pyroptosis.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"860-875"},"PeriodicalIF":13.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene therapies for neurogenetic disorders. 神经遗传疾病的基因治疗。
IF 13.8 1区 医学
Trends in molecular medicine Pub Date : 2025-09-01 Epub Date: 2025-02-17 DOI: 10.1016/j.molmed.2025.01.015
Orrin Devinsky, Jeff Coller, Rebecca Ahrens-Nicklas, X Shawn Liu, Nadav Ahituv, Beverly L Davidson, Kathie M Bishop, Yael Weiss, Ana Mingorance
{"title":"Gene therapies for neurogenetic disorders.","authors":"Orrin Devinsky, Jeff Coller, Rebecca Ahrens-Nicklas, X Shawn Liu, Nadav Ahituv, Beverly L Davidson, Kathie M Bishop, Yael Weiss, Ana Mingorance","doi":"10.1016/j.molmed.2025.01.015","DOIUrl":"10.1016/j.molmed.2025.01.015","url":null,"abstract":"<p><p>Pathogenic variants in over 1700 genes can cause neurogenetic disorders. Monogenetic diseases are ideal targets for genetic therapies; however, the blood-brain barrier (BBB), post-mitotic neurons, and inefficient delivery platforms make gene therapies for neurogenetic diseases challenging. Following nusinersen's 2016 approval, the development of gene therapies for neurogenetic disorders has advanced rapidly, with new delivery vehicles [e.g., BBB-crossing capsids, engineered viral-like proteins, lipid nanoparticles (LNPs)] and novel therapeutic strategies (e.g., regulatory elements, novel RNA therapeutics, tRNA therapies, epigenetic and gene editing). Patient-led disease foundations have accelerated treatment development by addressing trial readiness and supporting translational research. We review the current landscape and future directions in developing gene therapies for neurogenetic disorders.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"814-826"},"PeriodicalIF":13.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信